Open AccessSafety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma
Author(s) -
Matteo S. Carlino,
Shahneen Sandhu
Publication year - 2017
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2017.75.2055
Subject(s) - medicine , nivolumab , ipilimumab , melanoma , oncology , metastatic melanoma , expanded access , dermatology , immunotherapy , cancer , cancer research
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom